Products - Blood and bone marrow cancers | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 37 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 April 2025
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma [ID6334]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
7 May 2025
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 July 2025
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 August 2025
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 September 2025
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 October 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 October 2025
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 November 2025
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable ID3843
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC